BioAge Labs (BIOA) Current Deferred Revenue (2023 - 2026)

BioAge Labs (BIOA) has 4 years of Current Deferred Revenue data on file, last reported at $6.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 24.34% year-over-year to $6.2 million; the trailing twelve-month figure through Mar 2026 stood at $6.2 million (down 24.34% YoY), and the FY2025 full-year result was $5.8 million, down 26.48% from the prior year.
• Current Deferred Revenue rose to $6.2 million in Q1 2026, from $5.8 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $8.2 million in Q1 2025 to a low of $3.3 million in Q4 2023.
• A 4-year average of $6.6 million and a median of $7.5 million in 2025 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 136.22% in 2024 and decreased 26.48% in 2025, its largest moves.
• Tracing BIOA's Current Deferred Revenue over 4 years: stood at $3.3 million in 2023, then soared by 136.22% to $7.8 million in 2024, then declined by 26.48% to $5.8 million in 2025, then gained by 7.59% to $6.2 million in 2026.
• Business Quant data shows BIOA's Current Deferred Revenue at $6.2 million in Q1 2026, $5.8 million in Q4 2025, and $7.5 million in Q3 2025.